Just 113 investors made at least 2 equity insurtech investments during the year — a 72% drop from the high of 406 investors in 2021. As a result, insurtech dealmaking dropped to 362 deals, the lowest annual total since 2016.

Download the full report to access comprehensive data and charts on the evolving state of insurtech.

Key takeaways from the report include:

• Insurtech dealmaking and funding continue to decline. Deal count fell 28% year-over-year (YoY) to 362 deals in 2024, while funding dropped 4% to $4.5B. Insurtech deals and funding are both at recent lows.
• Quarterly funding to P&C insurtechs is in the gutter. P&C funding dropped 43% quarter-over-quarter (QoQ) to $0.4B in Q4’24 — a 7-year low — with annual funding also declining to $2.6B. The year’s 2 largest deals in P&C went to AI-focused startups Altana AI and Akur8, highlighting investors’ appetite for specialized AI opportunities.
• Silicon Valley is dethroned as insurtech’s funding capital. Silicon Valley’s share of global insurtech funding dropped dramatically from 20% in 2023 to 10% in 2024, surpassed by New York at 15%. This was the first time since 2018 that Silicon Valley wasn’t No. 1.
• Early-stage insurtechs raise record-high deal sizes. The median early-stage insurtech deal size surged 52% YoY to $3.8M in 2024 — outpacing the broader venture landscape — as investors concentrate on a more selective group of innovators.
• Recently funded insurtechs show stronger business fundamentals and more efficient growth trajectories. Insurtechs that raised funding in 2024 have grown employee headcounts by a median of 20% over the last 12 months, far surpassing the 3% growth among those that raised during the funding boom of 2021.

Insurtech dealmaking and funding continue to decline

Insurtech deal count fell 28% YoY, from 500 deals in 2023 to 362 in 2024. The decline outpaced the broader venture environment, which saw deal count fall 19% YoY. 2024 was the worst year for insurtech dealmaking since 2016 (328 deals).

Deal volume among leading investors has also decreased. The number of investors that made 5 or more equity insurtech investments has fallen from 57 in 2021 to just 7 in 2024. Those that remain active now operate in a more favorable environment due to reduced competition across the marketplace.

Insurtech funding declined in 2024 as well, though by only 4% YoY. 

CBI customers: Track 2.5K+ insurtech companies

Quarterly funding to P&C insurtechs is in the gutter

Q4’24 marked a 7-year low for P&C insurtech funding, which fell 43% QoQ to $0.4B. The decline caused broader insurtech funding to halve QoQ, from $1.4B in Q3’24 to $0.7B in Q4’24.

P&C deal count also fell 10% QoQ to 45 in Q4’24, the lowest level since Q2’16.

Annual P&C insurtech funding declined to $2.6B in 2024, a 7-year low, underscored by just 2 P&C insurtech startups raising $100M+ mega-round deals: Altana AI, which offers an AI-powered supply chain risk platform, and Akur8, an AI-powered pricing platform. Those deals signal appetite for specialized AI products for the insurance industry, coinciding with a global surge in AI funding to over $100B last year.

Comparatively, life & health insurtech saw an increase in annual funding and dealmaking. Funding increased 64% YoY to $1.8B in 2024, while deals ticked up from 126 in 2023 to 128 in 2024.

Silicon Valley is dethroned as insurtech’s funding capital

The share of global insurtech funding to Silicon Valley-based startups halved YoY, falling from 20% in 2023 to 10% in 2024. Comparatively, New York led the way with 15% of global insurtech funding share in 2024, more than doubling from 7% the year prior.

Silicon Valley is the world’s leading tech ecosystem, and venture-wide funding to the region’s startups soared last year amid a boom in AI investment. Given the ecosystem’s prominence, diminished insurtech activity in Silicon Valley could lead to missed opportunities for insurance-focused AI advancements.

See how Silicon Valley fared in the broader venture market

Early-stage insurtechs raise record-high deal sizes

The median insurtech deal size increased from $4.1M in 2023 to $5.2M in 2024.

The increase was fueled by early-stage insurtechs, which saw median deal size surge 52% YoY, from $2.5M in 2023 to $3.8M in 2024. The size and growth rate both beat out the broader venture environment, where early-stage deal size increased 17% YoY to $2.1M.

Combined with the broader decline in dealmaking, larger check sizes indicate that investors are concentrating their investments on fewer bets. For the insurance industry, this dynamic points to a slimmer insurtech landscape with fewer high-growth participants moving forward.

On the other hand, late-stage insurtech deal sizes declined 19% YoY from $40M in 2023 to $32.5M in 2024.

The decline coincides with a restricted exit environment: Insurtech M&A exits fell from 57 in 2023 to 35 in 2024. 

Nevertheless, notable exits include CCC Intelligent Solutions’s acquisition of EvolutionIQ in December at a valuation of $730M, as well as Applied’s purchase of Planck in July. Both acquisitions targeted genAI-enabled startups, signaling a broader appetite for genAI insurance offerings.

Recently funded insurtechs show stronger business fundamentals

Insurtechs that raised funding in 2024 are growing headcounts faster than other insurtechs, by a median of 20% over the last 12 months and 40% over the last 24 months.

Comparatively, median headcount growth among insurtechs that raised a funding round at the height of the funding boom in 2021 is marginal — just 3% over the last 12 months.

The higher growth rates of recently funded insurtechs suggest a new breed of companies with stronger fundamentals — they’re not only able to raise capital in a selective market but are also demonstrating more efficient growth than their 2021-funded counterparts.

By the same logic, investors and partners (like established brokers and carriers) should monitor the landscape for outliers that represent organic growth opportunities — such as insurtechs that haven’t raised funding in several years but continue to grow headcount at a steady clip.

See the fastest-growing insurtechs by headcount growth

MORE INSURTECH RESEARCH FROM CB INSIGHTS

• How genAI is reshaping the insurance value chain
• Insurtech 50: The most promising insurtech startups of 2024
• ITC Vegas 2024: Insurance is facing an AI inflection point
• Tech Transforming the World: The Game Changers Roundtable

For information on reprint rights or other inquiries, please contact reprints@cbinsights.com.

The post State of Insurtech 2024 Report appeared first on CB Insights Research.

However, global CVC deal count dropped to its lowest level since 2018 as CVCs become more selective.

Download the full report to access comprehensive data and charts on the evolving state of CVC across sectors, geographies, and more.

Key takeaways from the report include:

• CVC-backed funding grows, deal activity slows. Global CVC-backed funding increased 20% YoY to $65.9B, but deal count fell to 3,434, the lowest level since 2018. All major regions saw deal volume declines, with Europe dropping the most at 10% YoY.
• CVCs are all in on AI. AI startups captured 37% of CVC-backed funding and 21% of deals in 2024 — both record highs. Counter to the broader decline in deals, CVCs ratcheted up AI dealmaking by 13% YoY as they race to secure footholds in the space before competitors gain an insurmountable edge.
• The flight to quality continues. Among deals with CVC participation, the annual average deal size hit $27.3M in 2024, tied for the second highest ever. Amid fewer deals, CVCs are increasingly aggressive when they do decide to invest.
• Early-stage deals dominate. Early-stage rounds comprised 65% of 2024 CVC-backed deals, tied for the highest share in over a decade. Biotech startups made up half of the top 20 early-stage deals.
• CVC-backed funding plummets in Asia. In 2024, Asia’s CVC-backed funding dropped 34% YoY to $7B — the lowest level since 2016. China is leading the decline, with no quarter in 2024 exceeding $0.5B in funding. CVCs remain wary of investing in the country’s private sector.

We dive into the trends below.

CVC-backed funding grows, deal activity slows

Global CVC-backed funding reached $65.9B, a 20% YoY increase. The US was the main driver, increasing 39% YoY to $42.8B. Europe also saw CVC-backed funding grow 18% to $12.3B, while Asia declined 34% to $7B.

$100M+ mega-rounds also contributed to the rise, ticking up 21% YoY to 141 deals worth over $32B in funding.

Meanwhile, deal count continued its decline, as both annual (3,434 in 2024) and quarterly (806 in Q4’24) totals reached their lowest levels in 6 years.

Annual deal volume fell by at least 6% YoY across each major region — the US, Asia, and Europe — with Europe experiencing the largest decline at 10%.

However, Japan-based CVC deal volume remains near peak levels, suggesting a more resilient CVC culture compared to other nations. Two of the three most active CVCs in Q4’24 are based in Japan: Mitsubishi UFJ Capital (21 company investments) and SMBC Venture Capital (15).

Track recent activity from 1,000+ CVCs

CVCs are all in on AI

AI is driving CVC investment activity, much like the broader venture landscape. In 2024, AI startups captured 37% of CVC-backed funding and 21% of deals, both record highs.

In Q4’24, the biggest CVC-backed rounds went primarily to AI companies. These include:

• AI search startup Perplexity’s $500M Series C, backed by Nvidia’s NVentures 
• Coding AI copilot Poolside’s $500M Series B, backed by the venture arms for Citigroup, HSBC, Capital One, LG, eBay, and Nvidia
• AI computing processor developer Lightmatter’s $400M Series D, backed by GV

CVCs are also investing in the energy companies powering the AI boom, such as Intersect Power, which raised the largest round at $800M (backed by GV).

Expect the trend to continue into 2025, as emerging AI markets mature further, such as AI agents & copilots for enterprise and industrial use cases; AI solutions for e-commerce, finance, and defense; and the computing hardware necessary to power these technologies.

The flight to quality continues

In 2024, the annual average deal size with CVC participation reached $27.3M, a 34% YoY increase and tied for the second highest level on record, exceeded only by the low-interest-rate environment of 2021.​

Median deal size also increased, though only by 8% to $8.6M.

Even though the number of CVC-backed deals declined in 2024, the increase in average annual deal size reflects a focus on companies with strong growth prospects. CVCs are prioritizing quality and committing more funds to a select group of high-potential investments.

Early-stage deals dominate

Early-stage rounds (seed/angel and Series A) made up 65% of CVC-backed deals in 2024, tied for the highest recorded level in more than a decade.​

In Q4’24, biotech companies were the early-stage fundraising leaders, accounting for 10 of the 20 largest early-stage deals. Biotech players City Therapeutics, Axonis, and Trace Neuroscience all raised $100M+ Series A rounds, with City Therapeutics and Axonis notably receiving investment from the venture arms of Regeneron and Merck, respectively.

Among all early-stage CVC-backed companies, the largest round went to Physical Intelligence, a startup focused on using AI to improve robots and other devices. Physical Intelligence raised a $400M Series A with investment from OpenAI Startup Fund.

Explore CVCs’ top early-stage company targets in Q4

CVC-backed funding plummets in Asia

Asia’s CVC-backed funding continued its downward trend in 2024, decreasing 34% YoY to $7B.

China was the main driver, with CVC-backed funding coming in at $0.5B or less every quarter in 2024.​ CVCs remain wary of investing in startups in the nation, which faces a variety of economic challenges, including a prolonged real estate slump, cautious consumer spending, strained government finances, and weakened private sector activity amid policy crackdowns.

In Japan, on the other hand, CVC activity remains robust. In 2024, funding with CVC participation ($1.7B) remained on par with the year prior, while deals (502) actually increased by 11%.

MORE VENTURE RESEARCH FROM CB INSIGHTS

• State of Venture 2024 Report
• State of Fintech 2024 Report
• State of Digital Health 2024 Report

The post State of CVC 2024 Report appeared first on CB Insights Research.

Venture funding surged past the $100B mark for the first time as AI infrastructure players pulled in billion-dollar investments. A wave of M&A deals and rapidly scaling AI unicorns further underscored the tech’s momentum.

Download the full report to access comprehensive data and charts on the evolving state of AI across exits, top investors, geographies, and more.

Key takeaways include: 

• Massive deals drive AI funding boom. AI funding hit a record $100.4B in 2024, with mega-rounds accounting for the largest share of funding we’ve tracked to date (69%) — reflecting the high costs of AI development. Quarterly funding surged to $43.8B in Q4’24, driven by billion-dollar investments in model and infrastructure players. At the same time, nearly 3 in 4 AI deals (74%) remain early-stage as investors look to get in on the ground floor of the AI opportunity. 
• Industry tech sectors lose ground in AI deals. Vertical tech areas like fintech, digital health, and retail tech are securing a smaller percentage of overall AI deals (declining from a collective 38% in 2019 to 24% in 2024). The data suggests that companies focused on infrastructure and horizontal AI applications are drawing greater investor interest amid generative AI’s rise.
• Outside of the US, Europe fields high-potential AI startup regions. While the US dominated AI funding (76%) and deals (49%) in 2024, countries in Europe show strong potential in AI development based on CB Insights Mosaic startup health scores. Israel leads with the highest median Mosaic score (700) among AI companies raising funding. 
• AI M&A activity maintains momentum. The AI acquisition wave remained strong in 2024, with 384 exits nearly matching 2023’s record of 397. Europe-based startups represented over a third of M&A activity, cementing a 4-year streak of rising acquisitions among the region’s startups. 
• AI startups race to $1B+ valuations despite early market maturity. The 32 new AI unicorns in 2024 represented nearly half of all new unicorns. However, AI unicorns haven’t built as robust of a commercial network as non-AI unicorns, per CB Insights Commercial Maturity scores, indicating their valuations are based more on potential than proven business models at this stage.
• Tech leaders embed themselves deeper in the AI ecosystem. Major tech companies and chipmakers led corporate VC activity in AI during Q4’24, with Google (GV), Nvidia (NVentures), Qualcomm (Qualcomm Ventures), and Microsoft (M12) being the most active investors. This reflects the strategic importance of securing access to promising startups while providing them with essential technical infrastructure.

We dive into the trends below.

For more on key shifts in the AI landscape in 2025, check out this report on the implications of DeepSeek’s rise.

Massive deals drive AI funding boom

Globally, private AI companies raised a record $100.4B in 2024. At the quarterly level, funding soared to a record $43.8B in Q4’24, or over 2.5x the prior quarter’s total. 

The funding increase is largely explained by a wave of massive deals: mega-rounds ($100M+ deals) accounted for 80% of Q4’24 dollars and 69% of AI funding in 2024 overall.

The year featured 13 $1B+ deals, the majority of which went to AI model and infrastructure players. OpenAI, xAI, and Anthropic raised 4 out of the 5 largest rounds in 2024 as they burned through cash to fund the development of frontier models. 

Overall, the concentration of funding in mega-rounds reflects the high costs of AI development across hardware, staffing, and energy needs — and widespread investor enthusiasm around the AI opportunity. 

But that opportunity isn’t limited to the largest players: nearly 3 in 4 AI deals (74%) were early-stage in 2024. The share of early-stage AI deals has trended upward since 2021 (67%) as investors look to ride the next major wave of value creation in tech.

CBI Customers: Track 15,000+ AI companies

Industry tech sectors lose ground in AI deals

Major tech sectors — fintech, digital health, and retail tech — are making up a smaller percentage of AI deals.

While the overall annual AI deal count has stayed steady above 4,000 since 2021, dealmaking in sectors like digital health and fintech has declined to multi-year lows. So, even as AI companies make up a greater share of the deals that do happen in these industries, the gains haven’t been enough to register in the broader AI landscape.

The data suggests that, amid generative AI’s ascendancy, AI companies targeting infrastructure and horizontal applications are drawing a greater share of deals. 

With billions of dollars flowing to the model/infra layer as well, investors appear to be betting that the economic benefits of the latest AI boom will accrue to the builders.  

Outside of the US, Europe fields high-potential AI startup regions

Although US-based companies captured 76% of AI funding in 2024, deal activity was more distributed across the globe. US AI startups accounted for 49% of deals, followed by Asia (23.2%) and Europe (22.9%). 

Comparing median CB Insights Mosaic scores (a measure of private tech company health and growth potential on a 0–1,000 scale) for AI companies that raised equity funding in 2024 highlights promising regional hubs. 

Explore 500+ high-potential AI startups

European countries dominate the top 10 countries by Mosaic score (outside of the US). Israel, which has a strong technical talent pool and established startup culture, leads the pack with a median Mosaic score of 700.

Overall activity on the continent is dominated by early-stage deals, which accounted for 81% of deals to Europe-based startups in 2024, a 7-year high.

The European Union indicated in November that scaling startups is a top priority, pointing to the importance of increased late-stage private investment in remaining competitive on the global stage.

AI M&A activity maintains momentum

The AI M&A wave is in full force, with 2024’s 384 exits nearly reaching the previous year’s record-high 397.

Acquisitions of Europe-based startups accounted for over a third of AI M&A activity in 2024. Among the global regions we track, Europe is the only one that has seen annual AI acquisitions climb for 4 consecutive years. Although the US did see a bigger uptick YoY (16%) in 2024, posting 188 deals. 

In Europe, UK-based AI startups led activity in 2024, with 32 M&A deals, followed by Germany (18), France (16), and Israel (12). 

Major US tech companies, including Nvidia, Advanced Micro Devices, and Salesforce, participated in some of the largest M&A deals of the year as they embedded AI across their offerings.

Search for recently funded AI companies with high M&A probabilities

AI startups race to $1B+ valuations despite early market maturity 

AI now dominates new unicorn creation. The 32 new AI unicorns in 2024 accounted for nearly half of all companies passing the $1B+ valuation threshold during the year. 

These AI startups are hitting unicorn status with much smaller teams and at much faster rates than non-AI startups: 203 vs. 414 employees at the median, and 2 years vs. 9 years at the median. 

CBI Customers: Dive into data on every unicorn

These trends reflect the current AI hype — investors are placing big early bets on AI potential. Many of these unicorns are still proving out sustainable revenue models. We can see this clearly in CB Insights Commercial Maturity scores. More than half of the AI unicorns born in 2024 are at the validating/deploying stages of development, while non-AI new unicorns mostly had to get to at least the scaling stage before earning their unicorn status.

Tech leaders embed themselves deeper in the AI ecosystem

In Q4’24, the top corporate VCs in AI (by number of companies backed) were led by a string of notable names: Google (GV), Nvidia (NVentures), Qualcomm (Qualcomm Ventures), and Microsoft (M12). 

As enterprises rush to harness AI’s potential, big tech, chipmakers, and other enterprise tech players are building their exposure to promising companies along the AI value chain.

Meanwhile, startups are linking up with these players to not only secure funding for capital-intensive AI development but also access critical cloud infrastructure and chips.

MORE AI RESEARCH FROM CB INSIGHTS

• What DeepSeek’s model releases mean for the future of AI
• Here’s how leading strategy teams are successfully driving generative AI adoption in their organizations
• The foundation model divide: Mapping the future of open vs. closed AI development
• 15 tech trends to watch closely in 2025
• Inside the AI drug discovery arms race: Record M&A activity, a biologics funding spree, and more
• The industrial AI agents & copilots market map

For information on reprint rights or other inquiries, please contact reprints@cbinsights.com.

The post State of AI Report: 6 trends shaping the landscape in 2025 appeared first on CB Insights Research.

But only 32% of strategy leaders report active genAI deployments at their organizations.

To identify pain points and success stories for genAI adoption, we surveyed 50 senior strategy leaders working at companies across major industries.

Download the full report to understand how leading strategy teams navigate genAI adoption, their key challenges, and the tactics separating successful implementations from stalled initiatives.

For information on reprint rights or other inquiries, please contact reprints@cbinsights.com.

The post Here’s how leading strategy teams are successfully driving generative AI adoption in their organizations appeared first on CB Insights Research.

Mirroring trends in the broader venture market, AI proved to be a bright spot amid the downturn in digital health deals. In 2024, AI-focused companies secured 42% of digital health funding and accounted for 31% of deals — both record highs.

Download the full report to access comprehensive data and charts on the evolving state of digital health.

Key takeaways from the report include:

• Digital health dealmaking continues to decline. Despite a slight increase in funding YoY, digital health deal count dropped again in 2024, hitting its lowest annual total (1,225) since 2014. Regionally, Europe saw the sharpest drop in deals, with a 29% YoY decline.
• Fewer deals, bigger checks. The median digital health deal size jumped 39% YoY to hit a record high of $5.3M in 2024. The combination of declining deal volume and larger deal sizes suggests that selective investors are concentrating their resources on companies that meet heightened benchmarks in areas like clinical validation, commercial traction, and regulatory readiness.
• AI takes center stage in digital health. In 2024, AI-focused companies captured 42% of digital health funding and 31% of deals — both record highs. The 5 largest AI-focused digital health deals were spread across diagnostics, drug development, and women’s health.
• Digital health mega-rounds rebound in 2024. Mega-rounds ($100M+ deals) increased in 2024 after 2 years of decline, with the top 3 deals focused on drug discovery and development. Most top deals (7 out of 10) went to US-based companies, pointing to the region’s position as a hub for high-value digital health investment.

We dive into the trends below.

Digital health dealmaking continues to decline

Following 2 years of decline, digital health funding increased slightly in 2024, rising by 3% YoY.

However, digital health deal count fell for the third year straight in 2024. It dropped by 23% YoY to reach just 1,225 — its lowest level since 2014 — highlighting that investors remain cautious.

Regionally, Europe saw the steepest drop, with deal count shrinking 29% YoY to 258, despite a modest funding increase to $2.8B. Asia also experienced a decline, with deal count falling 19% YoY to 218, alongside a funding drop to $0.8B. While still the most active market, the US recorded a 19% YoY decline in deal count to 683, even as funding climbed to $11.7B.

CBI customers: Track 11K+ digital health companies

Fewer deals, bigger checks

While the overall deal count fell, the median digital health deal size surged in 2024.

It climbed by 39% YoY to reach $5.3M — a record high.

This combination of factors suggests that selective investors are prioritizing companies that meet heightened benchmarks in areas like clinical validation, commercial traction, and regulatory readiness.

CBI customers: See 180+ high-potential startups

AI takes center stage in digital health

AI is commanding a growing share of digital health investment activity.

AI-focused companies captured 42% of total digital health funding and 31% of deal volume in 2024 — both record highs. 

This surge reflects heightened investor confidence in AI’s ability to accelerate drug discovery, improve early disease detection, deliver personalized care, and more.

The top 2 AI-focused digital health deals in 2024 went to drug development platform Xaira Therapeutics. Freenome followed with a $254M Series F to expand its AI-driven early cancer detection tools, while Flo Health secured a $200M Series C to scale its personalized women’s health platform. BioAge Labs rounded out the top 5 with a $170M Series D to advance its AI-powered aging-related treatments.

Explore the top AI-focused digital health deals

As AI adoption grows across healthcare operations — from clinical and administrative workflows to drug development — healthcare providers and pharmaceutical giants will likely pursue strategic partnerships and acquisitions to maintain their competitive edge.

Digital health mega-rounds rebound in 2024

Digital health mega-round activity rebounded in 2024 after 2 consecutive years of decline, with deal count rising by 50% YoY to 33.

The top 3 mega-rounds of 2024 all went to drug discovery and development companies. 

Xaira Therapeutics led the pack with two $500M rounds for its AI-driven drug discovery and development platform, followed by Formation Bio with a $372M Series D to advance its drug development efforts. 

At the regional level, the US accounted for 7 of the top 10 mega-rounds in 2024, reflecting its position as a hub for high-value digital health investments. 

MORE DIGITAL HEALTH RESEARCH FROM CB INSIGHTS

• State of Digital Health Q3’24 Report
• AI’s moment in preclinical drug development arrives: Why formulation tech is the next frontier
• Inside the AI drug discovery arms race: Record M&A activity, a biologics funding spree, and more
• Digital Health 50: The most promising digital health startups of 2024
• The $4.6B opportunity in healthcare: Ambient AI to target clinician burnout

For information on reprint rights or other inquiries, please contact reprints@cbinsights.com.

The post State of Digital Health 2024 Report appeared first on CB Insights Research.

But beyond the momentum building in AI, global deal activity plunged 19% YoY to its lowest level since 2016, creating both challenges and opportunities for investors and corporate strategists.

Download the full report to access comprehensive data and charts on the evolving state of venture across sectors, geographies, and more.

Key takeaways from the report include:

AI is eating VC. In 2024, AI represented 37% of venture funding and 17% of deals — both all-time highs. AI infrastructure players raised all of the top 5 venture deals of the year, with 4 closing in Q4’24 alone — driving a 2-year high in quarterly funding. With nearly 3 in 4 (74%) AI deals being early-stage in 2024, investors are staking out early claims to reap the rewards of the tech’s potential.

Aside from AI, venture dealmaking is in a drought. Globally, deal activity fell 19% YoY to 27K in 2024 — its lowest annual level since 2016. The drop was most pronounced in countries like China (-33% YoY), Canada (-27%), and Germany (-23%). However, several countries in Asia — Japan, India, and South Korea — have bucked the downward trend. Their resilience suggests attractive investment conditions.

AI and industrial automation are common themes among the fastest-growing tech markets. Out of 1,400+ tech markets that CB Insights tracks, those with the highest rate of YoY deal growth include enterprise AI agents, genAI for customer support, industrial humanoid robots, and autonomous driving systems. Expect these technologies to continue maturing in 2025, increasing their disruptive potential.

Despite market uncertainty, early-stage valuations hit a record-high median of $25M in 2024. Investors are packing into early-stage rounds to ride the next major wave of value creation in tech, likely drawn by startups’ ability to now build products with less capital and fewer people thanks to AI tools and infrastructure. However, early-stage startups could face a reality check when they try to raise later-stage rounds if they have yet to prove they can sustain growth. Although mid- and late-stage deal valuations rebounded slightly vs. 2023, they remain muted compared to 2021 and 2022.

IPO timelines get delayed. From first funding to IPO, VC-backed companies that went public in 2024 waited a median of 7.5 years — 2 years longer than in 2022. Amid unfavorable market conditions, some late-stage players like Stripe and Databricks have resorted to raising additional equity funding or selling private shares in lieu of going public. This allows them to create liquidity for early investors and employees when the path to a public debut is rocky.

We dive into each trend below.

AI is eating VC

The 5 largest deals of the year all went to AI model and infrastructure players (led by Databricks’ $10B Series J, followed by a $6.6B round for OpenAI, two $6B rounds for xAI, and a $4B round for Anthropic). But the activity isn’t limited to the largest, most well-resourced AI players. 

Across the board, AI companies are capturing a higher share of deal volume — nearly one in 5 deals (17%) now go to AI companies, almost triple the share from 2015 (6%). AI deal volume remained above 4,000 for the fourth year in a row. 

CBI customers: Track 15,000+ AI companies

The boom is providing tailwinds for every stage of the startup lifecycle, from early-stage companies — which take 3 out of 4 deals in AI — to startup exits. The AI M&A wave is in full force, with 2024’s 384 exits nearly rivaling the previous year’s record-high 397.

This trend will continue in 2025 as incumbents look to grab AI tech and talent and build end-to-end AI offerings. Get the full breakdown of what AI M&A means for corporate strategy in our Tech Trends 2025 report.

In Q4’24, the AI boom helped fuel a substantial rebound in global funding. The quarter’s funding tally reached $86.2B — a 2-year high, and an increase of 53% quarter-over-quarter (QoQ).

60% of that quarterly total, or $52B, came from mega-rounds (deals worth $100M+) — nearly tying Q1’21 (61%) for the highest share ever across venture. 

At the same time, quarterly deal volume steadily declined throughout 2024, including slipping below 6,000 in Q4’24 for the first time since 2016.

Aside from AI, venture dealmaking is in a drought

Despite AI’s surge, most venture sectors face their worst dealmaking drought in nearly a decade, forcing investors to adjust their strategies. Many investors are taking a more selective and risk-off approach right now as they wait out macroeconomic volatility and geopolitical tensions.

Among major dealmaking countries and regions (those seeing 500+ deals per year), the slump was most pronounced in China (-33% YoY drop in deals), Canada (-27%), and Germany (-23%). 

However, several countries in Asia bucked the trend and notched slim YoY gains: Japan (+2%), India (+1%), and South Korea (+1%). These countries have invested heavily in developing their startup ecosystems and may be benefiting indirectly from investors diverting funds away from China.

AI and industrial automation are common themes among the fastest-growing tech markets

AI and industrial automation are at the center of some of the fastest-growing markets in tech.

We filtered CB Insights’ 1,400+ tech markets for those with at least 20 equity deals over the last 2 years, then singled out those with the strongest deal growth YoY in 2024.

The enterprise tech and industrials sectors dominate, comprising 9 of the top 10 tech markets. Advancements in generative AI are fueling much of the activity in areas like humanoid robots and autonomous driving systems. Investors are also backing tech companies improving industrial processes like water treatment and purification, with deals to the market more than doubling YoY.

The enterprise tech and industrials sectors are also seeing a wave of hiring, as they lead in YoY headcount growth among all sectors. Industrials markets saw an average of 11% headcount growth last year, followed by enterprise tech markets with 10%. 

Financial services and the consumer & retail industries are noticeably absent from the top 10 fastest-growing markets. Given the tough venture landscape, emerging technologies in these areas face an uphill battle.

CBI Market Index: Compare 1,400+ markets

Early-stage deals are showing strength

Globally, early-stage dealmaking represents one of the most vibrant areas of venture right now, with median deal size and valuation reaching all-time highs in 2024.

The seed/angel and Series A stages remain resilient despite the broader downturn, in part because investors view them as a safe haven to ride out late-stage challenges like constricted exit opportunities and capital constraints. Deal sizes and valuations for the mid- and late stages rebounded slightly vs. 2023 but were muted when compared to the boom times of 2021 and 2022.

Corporate strategy and development teams seeking out early-stage opportunities can see 900+ high-potential startups here. To identify these players, we looked at the nearly 11,000 VC-backed startups that raised seed or Series A rounds in 2024, then filtered for those with the healthiest businesses (600+ Mosaic score) and strongest management teams (600+ Management Mosaic score).

Explore 900+ high-potential early-stage startups

IPO timelines get delayed

Most tech firms continue to shirk the IPO market. Some are still waiting for macroeconomic conditions to stabilize, while others prefer to focus on topline growth without having to deal with the financial scrutiny that comes with being a public company.

This is pushing back the timelines for IPO-ready companies even further. 

From first funding to IPO, VC-backed companies that went public in 2024 waited a median of 7.5 years — 2 years longer than in 2022.

While Q4’24 saw an uptick in global IPOs, activity remains down vs. historical levels. In the current climate, many late-stage startups will likely opt instead to raise more private funding to sustain operations and pay out employees or early investors.

Search for recently funded companies with high IPO probabilities

Related resources from CB Insights:

• Live briefing on venture trends for 2025
• All AI research from CBI
• 15 tech trends to watch closely in 2025
• Game Changers 2025: 9 technologies that will change the world
• $1B+ Market Map: The world’s 1,249 unicorn companies in one infographic

The post State of Venture 2024 Report appeared first on CB Insights Research.

For pharma companies, it’s critical to maximize efficiency in preclinical development — the stage after drug discovery and before clinical trials — as poor processes can mask early warning signs of drug candidates that are likely to fail.

The stakes are high: Studies show that 90% of drugs fail in clinical trials. In Phase 1 trials alone — which have a median cost of $3.4M per trial — 40% of drug candidates fail.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post AI’s moment in preclinical drug development arrives: Why formulation tech is the next frontier appeared first on CB Insights Research.

Bringing a drug to market traditionally involves staggering costs — averaging $1.3B when accounting for all failed compounds — and costs continue to rise as productivity in the drug R&D process declines. 

AI has the potential to break this pattern by dramatically accelerating drug discovery and reducing costs.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Inside the AI drug discovery arms race: Record M&A activity, a biologics funding spree, and more appeared first on CB Insights Research.

Liquid biopsy tests also offer the ability to track treatment response, detect resistance early, and adjust therapy dynamically — advantages that could improve outcomes while reducing failed treatment costs.

As incumbents look to expand their footprint in oncology tech, there are several key shifts in the liquid biopsy landscape to watch:

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The next big cancer tech acquisition could be one of these 5 liquid biopsy players appeared first on CB Insights Research.

But the overall slowdown only tells part of the story. Within this smaller pool of new billion-dollar companies, AI startups have come to dominate, comprising 44% of new unicorns this year — a 7x increase in share over the last decade.

Here’s what today’s unicorn landscape signals about the future of tech:

• AI dominates new unicorn creation — 2024 has seen 72 companies become unicorns, and 32 of these (44%) are AI startups. These AI players are reaching unicorn status far faster (median of 2 years) than non-AI companies (median of 9 years). As AI capabilities advance at a rapid pace — across domains from intelligent robotics to coding AI agents — corporations that delay AI adoption risk falling behind their competitors.
• Valuations are under pressure — Over one-third of the 1,200+ current unicorns haven’t raised funding since 2021, and over 100 of these companies were last valued at exactly $1B — meaning a down round would take their unicorn status away altogether. These represent potentially distressed assets that cash-rich incumbents and corporate development teams would want to snap up.
• Next in line for an exit — Among today’s unicorns, 110 stand out with IPO probabilities above 20% (anywhere from 31x to 64x that of the average company we track). Another 25 have equally high M&A probability scores, making them prime acquisition targets for incumbents looking to expand their tech and market reach.

Market map of billion-dollar startups

On paper, today’s unicorns are collectively worth over $4T. 

However, it’s unlikely that many of these 1,200+ companies are worth as much as their latest valuation, given how dramatically the venture landscape has changed since the heady days of 2021/22. Since then, tighter capital markets have applied downward pressure on public and private tech company valuations alike.

Over one-third of current unicorns haven’t raised a funding round since 2021. If they were to raise in today’s climate, they’d likely face a valuation cut. That includes over 100 unicorns that were last valued at exactly $1B — meaning any valuation reduction would strip them of their unicorn status.

CBI customers: Dive into data on every unicorn

With venture funding at its lowest level since 2016/17, unicorns in need of cash are likely considering an exit. Some have been waiting years for the IPO market to open up so they can access capital and compensate employees without further diluting their business. Others will need to accept sales at discounted prices.

Unicorns most likely to exit via IPO or M&A

Per CB Insights’ Exit Probability scores — which measure a company’s likelihood to exit in the next 2 years, based on 70+ data points — a select cohort of unicorns emerges as the most likely candidates for IPO and M&A. 

110 unicorns have a 20% or higher chance of IPO’ing in the next 2 years — anywhere from 31x to 64x the likelihood of the average company we track. Recent tech IPOs have performed well relative to the cold snap of 2022/23, particularly for companies benefiting from the AI boom. This will likely open the doors to other IPO hopefuls like Klarna, which is reportedly considering debuting as soon as H1’25.

A smaller segment of unicorns has an M&A exit probability of 20%+ (from 2x to 5x the average). This includes unicorns like AI data company Tresata (38% M&A probability) and fleet management & telematics provider Radius (33%), both of which have faced headcount reductions over the last year.

These acquisition targets could offer incumbents a way to quickly add new tech and talent as well as expand their customer base and market reach.

See the IPO and M&A probabilities for every unicorn

AI has become a unicorn factory

The current AI boom is a driving force behind new unicorn creation. 

In 2024 so far, 44% of new unicorns have been AI companies. This is by far the highest share that AI has seen over the past decade, representing over 7x growth during that time (from 6% in 2015).

What’s more, these AI startups are hitting unicorn status with 1) much smaller teams and 2) at much faster rates.

Among new unicorns in 2024, the median AI unicorn has just 203 employees and reached unicorn status in 2 years from its founding date. For comparison, the median non-AI company to become a unicorn did so with double the team size (414 employees) and a much longer life-span (9 years).

The size of these AI teams — and the speed with which they attain unicorn status — points to several underlying factors. For one, today’s AI startups may be able to do more with less — they can use their AI expertise to automate certain functions and scale faster with less staffing than a non-AI company. 

But there’s a likely bigger factor at play: With the current pace of AI advances, alongside the sheer amount of AI hype, AI startups are able to earn investors’ attention earlier and with less to show for their business than non-AI companies. The AI opportunity means many of these startups can bank on fast revenue growth, though it’s unclear how sustainable that is — or when, if ever, that revenue will translate into profit. 

Nevertheless, the breadth of the AI opportunity — across industries, business models, and audiences — means that there is still plenty of white space for these startups to carve out niches.

Among this year’s new unicorns, some of the smallest AI teams include:

• World Labs: 18 employees (founded 2024, valued at $1B)
• Skild AI: 19 employees (founded 2023, valued at $1.5B)
• Sakana AI: 34 employees (founded 2023, valued at $1.5B)
• Cognition AI: 49 employees (founded 2023, valued at $2B)
• Poolside: 75 employees (founded 2023, valued at $3B)

Notably, these startups point to several emerging areas of opportunity in AI:

Intelligent robotics and embodied AI — Both World Labs and Skild AI are working toward making AI systems that can better understand and interact with the physical world. This is also an area where OpenAI is getting involved, via investments in other unicorns like Figure and Physical Intelligence.

Coding AI agents & copilots — Cognition AI and Poolside both focus on automating software engineering. Equity funding to coding AI agents & copilots has exploded this year, nearly tripling to reach $1.8B.

RELATED RESEARCH FROM CB INSIGHTS:

• 15 tech trends to watch closely in 2025
• State of Venture Q3’24 Report
• Future of the workforce: How AI agents will transform enterprise workflows
• Future Tech Hotshots: 52 emerging tech startups that will have big, successful exits

The post $1B+ Market Map: The world’s 1,249 unicorn companies in one infographic appeared first on CB Insights Research.

For health system CIOs, digital health investors, and life sciences executives, this list spotlights companies to explore for technology adoption, investment opportunities, and strategic partnerships as healthcare shifts toward AI-driven infrastructure, advanced diagnostics, and specialized care platforms.

Four key themes emerged from this year’s cohort:

• • AI will become foundational to infrastructure across healthcare, as evidenced by 36 of the 50 companies building AI products, from insurance claim copilots (Alaffia Health) to specialized healthcare LLMs (Hippocratic AI). These startups reflect the start of a broader shift for AI from powering point solutions to becoming an essential part of healthcare delivery for patients.
  • Diagnostic innovations continue to dominate, representing the most crowded category on last year’s list and tying for the largest category this year, with 11 companies developing tools across imaging (Airs Medical), pathology (Proscia), and non-invasive diagnostics (Alimetry). These next-generation diagnostics look to make testing more accessible and non-invasive while prioritizing early detection.
  • Virtual and hybrid care companies more than doubled in this year’s cohort, with 11 companies in this category, up from 5 last year. The increase reflects the growing number of specialized platforms in areas including mental health (Talkiatry) and cancer care (Resilience), signaling the shift from general telemedicine toward condition-specific virtual care models.
  • Workflow efficiency emerges as a key priority heading into 2025, with 19 companies streamlining administrative and clinical tasks, from medical document processing (Tennr) to ambient documentation (Abridge). The surge of automation solutions here signals that healthcare organizations will prioritize efficiency amid staffing shortages to help shift provider time from paperwork to patient care. 

Discover all 50 winners in the Expert Collection

Our selection of winning companies followed a rigorous three-step process.

From a pool of 10,000+ digital health startups, we analyzed companies using CB Insights’ proprietary metrics — Commercial Maturity and Mosaic scores — along with additional data on partnerships, funding, patents, leadership, and headcount.

Companies with high Mosaic scores (> 500) and recent market activity advanced to our shortlist of 1,500 candidates. We supplemented this analysis with direct company submissions via Analyst Briefings.

Our analysts then evaluated strategic partnerships, market adoption, and growth metrics to identify the 50 most promising digital health companies.

2024 DIGITAL HEALTH 50 COHORT HIGHLIGHTS 

Funding and deals

The 2024 Digital Health 50 companies have raised $3.5B across 171 disclosed equity deals (as of 11/14/2024). Monogram Health and Abridge lead the cohort in disclosed equity funding, with $555M and $208M, respectively.

In 2024 so far, the cohort has raised $1.6B across 47 disclosed equity deals. The largest deals include:

• Abridge — $150M Series C
• Superluminal Medicines — $120M Series A
• Grow Therapy — $88M Series C
• CytoReason — $80M Series A
• Ambience — $70M Series B

The recipients of these top deals are largely focused on 2 AI applications: streamlining clinical documentation (Abridge and Ambience) and accelerating drug discovery (Superluminal Medicines and CytoReason).

See all equity deals raised by the 2024 DH 50

Stage breakdown

Fifty-six percent of the 2024 Digital Health 50 companies are early-stage (seed or Series A). In comparison, 44% of winners are mid-stage (primarily Series B or C) companies.

Top investors

Andreessen Horowitz leads VC investors (including CVCs) in the number of 2024 Digital Health 50 winners backed (8). Its investments span various areas within digital health, including:

• D2C health testing — Function Health
• Clinical intelligence — Ambience, Hippocratic AI, Scribenote
• Virtual & hybrid care — Talkiatry, Pomelo Care
• Price transparency — Turquoise Health
• Administrative workflow optimization — Tennr

Andreessen Horowitz is followed by BoxGroup, General Catalyst, and NVentures (Nvidia’s venture arm), each with 5 winners backed. 

All 5 of NVentures’ portfolio companies are building AI products. They are split between clinical intelligence (Hippocratic AI, Abridge, Artisight) and drug discovery (Iambic Therapeutics, Superluminal Medicines).

Healthcare systems and other big tech players are also active investors in the 2024 Digital Health 50. Mayo Clinic, Memorial Hermann, and Google Ventures have each invested in 3 companies on this year’s list.

Geographic distribution

This year’s Digital Health 50 companies are headquartered across 9 countries. Most companies (36) are based in the United States.

Germany has the largest representation outside of the US — 3 companies are headquartered in the country. It is followed by Canada, Israel, South Korea, and the United Kingdom, each with 2 companies. 

Additional countries represented include New Zealand, Belgium, and France, each with 1 company.

Headcount growth

The 2024 Digital Health 50 companies collectively employ more than 7,500 people, with 4 companies employing about 40% of the cohort’s workers: Grow Therapy, Nourish, Monogram Health, and Octave. 

Three companies — Tennr, Nourish, and Pomelo Care — have demonstrated the strongest headcount growth over the past year, with 12-month (September 2023–2024) headcount increases of 320%, 250%, and 244%, respectively. 

This year’s winners collectively created more than 2,900 jobs over the period, with Grow Therapy creating the most jobs (800).

The median 2024 Digital Health 50 winner has raised $487K in equity funding per employee. Superluminal Medicines leads the pack, raising $8.1M per employee, followed by Chai Discovery ($4.3M) and Iambic Therapeutics ($2.6M).

Company health

The average Mosaic score — a proprietary measure of private company health and growth potential — for the 2024 Digital Health 50 is 771 out of 1,000 (as of 11/14/2024). 

Forty companies in this year’s cohort have a Mosaic score of 700 or higher, placing them among the top 4% of private companies tracked by CB Insights. 

Midi and Nourish lead the cohort with the highest scores — 932 and 887, respectively.

The post Digital Health 50: The most promising digital health startups of 2024 appeared first on CB Insights Research.

Using CB Insights data, we uncovered 4 strategic priorities highlighted by Roche’s acquisitions, investments, and partnerships since Q1’23. We then categorized companies by their relationships with Roche across these priorities.

Here are 3 key takeaways from our analysis:

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Roche targets two emerging battlegrounds — obesity and AI diagnostics — for its next growth phase appeared first on CB Insights Research.

Our 2025 Tech Trends report provides a concrete roadmap for corporate leaders to navigate some of the most important technology shifts in the year ahead.

We include specific recommendations for action so that business leaders can get ahead of the next wave of value creation.

Here is a selection of key findings from the report:

• AI agents are given money to spend: AI agents’ utility is limited until they can make transactions seamlessly. A small group of tech players is building new infrastructure to make that happen.
• The future data center arrives: With data center power usage expected to more than double by 2026, big tech companies are morphing into energy innovators to support AI workloads. There’s a huge opportunity in improving data centers’ energy efficiency.
• Investment floodgates open for RNA therapeutics: RNA therapeutics developers are pioneering new ways to treat traditionally “undruggable” diseases, with a growing focus on neurodegenerative disorders like Alzheimer’s and Huntington’s diseases.
• AI M&A fuels the next wave of corporate strategy: AI’s share of corporate tech M&A has doubled since 2020. Tech incumbents like Nvidia, Salesforce, and Snowflake, as well as consultancies like Accenture, are rapidly acquiring AI startups to tap into enterprise demand. 
• Disease management enters a new phase with AI: AI is improving care delivery across 3 key areas of disease management: precise symptom evaluation; testing/screening for earlier disease detection (including before symptoms even appear); and finding at-risk individuals in datasets of entire patient populations. 
• Retail’s personalization imperative: Generative AI is unlocking 1:1 experiences across commerce touchpoints, with leaders like Target seeing a corresponding 3x boost in conversation rates. Personalization will become omnipresent in retailers’ offerings.
• And much more

Methodology

Our analysis relies on a wide range of CB Insights datasets, including financing and acquisition data, valuations, founding team and key people data, earnings transcripts, and more. We also leverage CB Insights’ proprietary scoring algorithms to measure business health (Mosaic) and maturity (Commercial Maturity), as well as the likelihood of acquisition (M&A Probability score). Throughout the report, we provide CB Insights customers with jumping-off points to dig deeper into the data behind the report.

The post 15 tech trends to watch closely in 2025 appeared first on CB Insights Research.

In response, robotics companies are seeing an opportunity to deploy their solutions across the healthcare industry — from automated medication dispensing to robotics-assisted physical therapy. Broader interest in the space is also rising, with healthcare robotics news mentions reaching a new high in October.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post Robots are coming for healthcare — here are the emerging hotspots according to recent deals appeared first on CB Insights Research.

Explore AI-focused exhibitors and sponsors from the conference

This AI focus reflects a new reality for insurers: Incumbents will need to move quickly to evaluate emerging AI products or risk being left behind by fast-moving competitors.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post ITC Vegas 2024: Insurance is facing an AI inflection point appeared first on CB Insights Research.

Q3’24 also saw the most selective dealmaking environment in years, although there were notable bright spots — in the early stages of funding, in the life & health insurance segment, and among France’s insurtechs.

Download the full report to access comprehensive data and charts on the evolving state of insurtech across sectors, geographies, and more.

Below, we cover key shifts in the landscape, including:

Quarterly insurtech funding holds mostly steady from Q2’24, at $1.4B. In Q3, the funding was evenly split across both P&C and life & health (L&H) segments — one of just 3 quarters since 2020 where L&H insurtechs have rivaled P&C for quarterly funding.

Insurtech fared better in Q3’24 than the broader venture environment, which saw funding decrease 20% quarter-over-quarter (QoQ). In fact, on a year-over-year basis, insurtech funding grew in Q3 by 27%.

A majority of insurtech funding goes to $100M+ mega-round deals for the first time since Q3’22. Q3’24 saw mega-round funding and deals — $0.8B across 5 deals — surge to a 2-year high.

Altana AI, which offers a supply chain risk platform, raised the largest insurtech equity deal in 2024 so far ($200M Series C) from investors including Google Ventures and Salesforce Ventures. The deal valued Altana AI at $1B, making it the first new insurtech unicorn of 2024 so far. Insurtechs that offer Medicare Advantage plans raised 2 of the other mega-round deals, Devoted Health ($112M Series E) and Zing Health ($140M Series A).

Insurtech deal count falls to an 8-year low. Q3’24 saw global insurtech deal count decline to 77, falling 10% QoQ and 42% YoY. Q2’16 was the last quarter to see fewer insurtech deals (60). 

Even so, the drop is in line with a broader decline in venture dealmaking. Also, across insurtech and the broader venture environment, the percentage of deals by deal stage (i.e., early, mid-, late, or other) has been without drastic swings in recent years.

The median early-stage insurtech deal size has reached a record high, increasing from $2.5M in 2023 to $4M in 2024 so far. This signals that investors remain bullish on early-stage dealmaking despite the broader decline in funding and deals. 

Comparatively, the median early-stage insurtech deal size only reached $3M in 2022 amid the venture funding boom.

Three of the 10 largest insurtech deals in Q3’24 were early-stage.

France-based insurtechs raise 83% of Europe’s insurtech funding in Q3. Five France-based insurtechs raised a combined $385M in Q3’24, including mega-round deals for health insurer Alan ($193M Series F) and pricing platform Akur8 ($120M Series C). 

Globally, only insurtechs from France and the US appeared among the 10 largest insurtech deals of the quarter.

RELATED RESEARCH FROM CB INSIGHTS:

• State of Venture Q3’24 Report
• State of Insurtech Q2’24
• Insurtech 50: The most promising insurtech startups of 2024
• How genAI is reshaping the insurance value chain
• Game Changers 2025: 9 technologies that will change the world
• Tech Transforming the World: The Game Changers Roundtable (Webinar)

The post State of Insurtech Q3’24 Report appeared first on CB Insights Research.

This spending is creating opportunities for growth across the AI data center value chain.

Want to see more research? Join a demo of the CB Insights platform.

If you’re already a customer, log in here.

The post The AI data center value chain: 12 high-momentum technologies powering the future of AI appeared first on CB Insights Research.

Despite these declines, $100M+ mega-rounds comprised 51% of total CVC-backed funding in Q3’24, a notable increase from a quarterly average of 37% in 2023. Meanwhile, two-thirds of CVC deals this year have gone to early-stage companies, highlighting a strategic shift toward more emerging opportunities, especially in AI.

Based on our deep dive in the full report, here is the TL;DR on the state of CVC:

• ​​Global CVC-backed funding drops 5% to $15.7B in Q3’24. Nevertheless, that figure is still the second-highest quarterly level since the beginning of 2023. Meanwhile, a 10% QoQ decline to 773 deals — the lowest total since 2018 — suggests that CVCs are increasingly selective, similar to the wider venture market.

• The average CVC-backed deal size has increased 31% so far this year to $27.1M, highlighting investors’ willingness to take risks when they find the right opportunity. However, the median deal size remains the same as last year at $8M, signaling that investors are only more aggressive regarding the largest deals.

• Funding to CVC-backed mega-rounds (deals worth $100M+) represents 51% of total funding in Q3’24. This percentage — roughly in line with the first 2 quarters of 2024 — is up significantly from an average of 37% in 2023, further suggesting that investors are currently willing to make large bets when they decide to invest.
• Early-stage rounds represent 66% of total CVC deal share this year, the highest level in over a decade. CVCs are increasingly focused on early-stage startups, likely driven by the record levels of AI funding and the fact that, across investor types, 72% of deals to AI companies this year are early-stage.

• CVC-backed funding in the US ticks up to $10.5B. Among major global regions, the US continued to lead in CVC-backed funding in Q3’24, followed by Europe at $2.6B and Asia at $1.3B. Within the US, defense tech provider Anduril raised the largest CVC-backed deal with its $1.5B Series F round (CVC investors include Franklin Venture Partners), followed by AI chip developer Groq with its $640M Series D round (backed by Samsung Catalyst).

MORE VENTURE RESEARCH FROM CB INSIGHTS

• State of CVC Q2’24 Report
• State of Venture Q3’24 Report
• State of Fintech Q3’24 Report
• State of Digital Health Q3’24 Report

The post State of CVC Q3’24 Report appeared first on CB Insights Research.